

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254,
Wellington 6001, New Zealand
Phone 64 - 4 - 460 4990
Fax 64 - 4 - 460 4995
www.pharmac.govt.nz

31 May 2006

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

Proposal to list candesartan (Atacand) 32 mg tablets

PHARMAC is seeking feedback on a proposal in relation to the listing of AstraZeneca Limited's 32 mg strength of candesartan (Atacand). Details of the proposal follow:


PHARMAC would list candesartan (Atacand) 32 mg tablets in Section B and in Part II of Section H of the Pharmaceutical Schedule at the following price and subsidy:

Pharmaceutical	Form	Strength	Brand	Pack Size	Price and Subsidy
Candesartan	Tablet	32 mg	Atacand	30	\$42.80

Listing in Section B of the Pharmaceutical Schedule, would be subject to the current candesartan Special Authority criteria and a "No more than 1 tab per day" restriction.

It is anticipated that the proposed changes, if approved by PHARMAC's Board (or Chief Executive), would take effect from 1 August 2006. If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to Stephen Woodruffe at PHARMAC by **5:00 pm, 14 June 2006**.

Yours sincerely



Stephen Woodruffe
Therapeutic Group Manager Intern